- Global Pharma News & Resources

Thermo Fisher Scientific Announces Receipt of All Required Regulatory Approvals for Proposed Acquisition of Patheon

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that all required antitrust clearances have been obtained for the previously announced all-cash tender offer by its wholly owned subsidiary, Thermo Fisher (CN) Luxembourg S.à r.l., to purchase all of the outstanding ordinary shares of Patheon N.V. (NYSE: PTHN).

Competition authorities in Brazil approved the transaction on August 7, 2017, initiating a 15 calendar-day comment period, which expired on August 22, 2017. Additionally, the European Commission approved the transaction today.

As a result of the antitrust approvals, Thermo Fisher expects to complete the tender offer promptly following the expiration of the offer, which is scheduled to expire at 5:00 p.m., New York City time, on August 28, 2017.  Completion of the tender offer is subject to the satisfaction of conditions described in the tender offer statement on Schedule TO filed by Thermo Fisher with the U.S. Securities and Exchange Commission on May 31, 2017 (as amended and supplemented, the "Schedule TO").

American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, has advised Thermo Fisher that as of 5:00 p.m., New York City time, on August 22, 2017, 120,161,513 Patheon ordinary shares, representing approximately 82.8% of the outstanding Patheon ordinary shares, had been validly tendered pursuant to the tender offer and not properly withdrawn.

D.F. King & Co. is acting as information agent for the tender offer. Requests for documents and questions regarding the tender offer may be directed to D.F. King toll free at 800-487-4870 (for shareholders) or collect at 212-269-5550 (for banks and brokers).